LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Editorial: A multidisciplinary approach to treatment of severe chronic airway disease (CAD): focus on biomarkers.

López-Rodríguez, Raquel / Bobolea, Irina / Melero, Carlos / Rial, Manuel J

Frontiers in allergy

2024 Volume 5, Page(s) 1357886

Language	English
Publishing date	2024-02-02
Publishing country	Switzerland
Document type	Editorial
ISSN	2673-6101
ISSN (online)	2673-6101
DOI	10.3389/falgy.2024.1357886
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Inflammatory Remission in T2 Severe Asthma.

Rial, Manuel J / Domínguez-Ortega, Javier

Frontiers in allergy

2022 Volume 3, Page(s) 923083

Language	English
Publishing date	2022-05-30
Publishing country	Switzerland
Document type	Journal Article
ISSN	2673-6101
ISSN (online)	2673-6101
DOI	10.3389/falgy.2022.923083
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.

Padró, Clara / Gutiérrez, Diego / Moreno, Francisco / Parra, Antonio / Rial, Manuel J / Lleonart, Ramón / Torán-Barona, Carla / Justicia, José L / Roger, Albert

Immunity, inflammation and disease

2022 Volume 10, Issue 5, Page(s) e585

Abstract: Introduction: Although clinical trials have shown the efficacy and safety of allergen-specific immunotherapy (AIT) in the treatment of allergic asthma, there is a need for real-life studies. We aimed to assess the effectiveness and safety of a ... ...

Abstract	Introduction: Although clinical trials have shown the efficacy and safety of allergen-specific immunotherapy (AIT) in the treatment of allergic asthma, there is a need for real-life studies. We aimed to assess the effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid (Acarovac Plus®) in patients with house dust mite (HDM)-induced allergic asthma in a real-life study. Methods: A subanalysis of a multicenter, prospective, observational, real-life study. Patients with rhinitis and allergic asthma caused by HDMs were assessed before AIT with Acarovac Plus® and at 6 and 12 months after this treatment. Assessment parameters were percentage of days with asthma symptoms, percentage of days on asthma medication, classification of asthma according to Spanish guidelines for the management of asthma, asthma-related quality of life (quality of life in adults with asthma questionnaire [QLAAQ]), perception of symptoms (visual analog scale [VAS]), and treatment satisfaction (treatment satisfaction questionnaire for medication [TSQM]). Safety was assessed by the number and severity of adverse reactions. Results: This subanalysis included 55 patients. Treatment with Acarovac Plus® showed significant differences in the analyzed variables when the baseline visit was compared with the 12-month visit: reduction of the mean (SD) percentage of days with asthma symptoms (23.9 [9.2] vs. 5.1 [12.8]; p = .002), of the mean [SD] percentage of days on asthma medication (67.6 [42.9] vs. 45.1 [46.8]; p = .002), and of the percentage of patients with persistent asthma (78.2% vs. 38.9%; p = .009). Acarovac Plus® significantly improved asthma-related quality of life, as shown by a decrease of 1.39 points in QLAAQ score at 12 months (p < .001), and in the subjective perception of symptoms on the VAS (-3.50, p < .0001). Patients showed high treatment satisfaction according to the TSQM, and it was well tolerated. No serious adverse events were reported. Conclusions: Acarovac Plus® was effective and safe for the treatment of patients with HDM-induced allergic asthma in a real-life study.
MeSH term(s)	Adjuvants, Immunologic ; Adult ; Allergoids ; Animals ; Antigens, Dermatophagoides/therapeutic use ; Asthma/drug therapy ; Dermatophagoides pteronyssinus ; Desensitization, Immunologic/adverse effects ; Humans ; Prospective Studies ; Pyroglyphidae ; Quality of Life ; Rhinitis ; Tyrosine/chemistry
Chemical Substances	Adjuvants, Immunologic ; Allergoids ; Antigens, Dermatophagoides ; Tyrosine (42HK56048U)
Language	English
Publishing date	2022-04-27
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2740382-8
ISSN	2050-4527 ; 2050-4527
ISSN (online)	2050-4527
ISSN	2050-4527
DOI	10.1002/iid3.585
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long and winding road: from infant wheeze to adult asthma.

Sánchez-García, Silvia / Rial, Manuel J / Domínguez-Ortega, Javier

Current opinion in pulmonary medicine

2019 Volume 26, Issue 1, Page(s) 3–9

Abstract: Purpose of review: This review aims to recognize the multifactorial cause of asthma, from the influence of mother until adulthood, highlight the main characteristics of the disease at different ages and summarize the evidence of potential prevention ... ...

Abstract	Purpose of review: This review aims to recognize the multifactorial cause of asthma, from the influence of mother until adulthood, highlight the main characteristics of the disease at different ages and summarize the evidence of potential prevention strategies. Recent findings: To date, regarding the prenatal period, the presence of specific genes, maternal asthma, drugs, and tobacco exposure are the most relevant predisposing features for an asthmatic offspring. For newborns, preterm, bronchopulmonary dysplasia, and low birth weight has been associated with low lung function. Among young children, atopic dermatitis, lower respiratory tract infections, and increased levels of total Immunoglobulin E (IgE) and allergen-specific IgE are important determinants.Breastfeeding has been demonstrated being protective for the onset of asthma. Allergen immunotherapy has also been shown to have significant preventive effect decreasing asthma development. Inhaled corticosteroids use in early childhood prevents exacerbations but does not alter the natural history of asthma. Other interventions, such as the use of palivizumab, probiotics, vitamin D supplementation, and fish consumption presented controversial results. Summary: A good knowledge of risk factors for asthma development, from prenatal period to adulthood, may lead to efficacious preventive strategies. Further data of long-term follow-up in population-based studies according to different phenotypes are needed.
MeSH term(s)	Asthma/epidemiology ; Asthma/prevention & control ; Causality ; Disease Management ; Disease Susceptibility ; Humans ; Preventive Health Services/methods ; Risk Factors
Language	English
Publishing date	2019-11-04
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1285505-4
ISSN	1531-6971 ; 1070-5287 ; 1078-1641
ISSN (online)	1531-6971
ISSN	1070-5287 ; 1078-1641
DOI	10.1097/MCP.0000000000000643
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4900: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma.

Rial, Manuel J / Cañas, José A / Rodrigo-Muñoz, José M / Valverde-Monge, Marcela / Sastre, Beatriz / Sastre, Joaquín / Del Pozo, Victoria

International journal of molecular sciences

2021 Volume 22, Issue 7

Abstract: There is currently enough evidence to think that miRNAs play a role in several key points in asthma, including diagnosis, severity of the disease, and response to treatment. Cells release different types of lipid double-membrane vesicles into the ... ...

Abstract	There is currently enough evidence to think that miRNAs play a role in several key points in asthma, including diagnosis, severity of the disease, and response to treatment. Cells release different types of lipid double-membrane vesicles into the extracellular microenvironment, including exosomes, which function as very important elements in intercellular communication. They are capable of distributing genetic material, mRNA, mitochondrial DNA, and microRNAs (miRNAs). Serum miRNA screening was performed in order to analyze possible changes in serum miRNAs in 10 patients treated with reslizumab and 6 patients with mepolizumab after 8 weeks of treatment. The expression of miR-338-3p was altered after treatment (
MeSH term(s)	Adult ; Anti-Asthmatic Agents/pharmacology ; Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Asthma/genetics ; Biomarkers/blood ; Female ; Gene Expression Regulation/drug effects ; Humans ; Interleukin-5/antagonists & inhibitors ; Male ; MicroRNAs/blood ; Middle Aged ; Treatment Outcome
Chemical Substances	Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; Biomarkers ; IL5 protein, human ; Interleukin-5 ; MIRN338 microRNA, human ; MicroRNAs ; reslizumab (35A26E427H) ; mepolizumab (90Z2UF0E52)
Language	English
Publishing date	2021-03-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms22073558
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.

Del Pozo, Victoria / Bobolea, Irina / Rial, Manuel J / Espigol-Frigolé, Georgina / Solans Laqué, Roser / Hernández-Rivas, Jesús María / Mora, Elvira / Crespo-Lessmann, Astrid / Izquierdo Alonso, José Luis / Domínguez Sosa, María Sandra / Maza-Solano, Juan / Atienza-Mateo, Belén / Bañas-Conejero, David / Moure, Abraham L / Rúa-Figueroa, Íñigo

Frontiers in immunology

2024 Volume 14, Page(s) 1310211

Abstract: Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. ... ...

Abstract	Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.
MeSH term(s)	Humans ; Glucocorticoids/adverse effects ; Churg-Strauss Syndrome ; Consensus ; Eosinophils ; Granulomatosis with Polyangiitis ; Leukocyte Disorders ; Biological Products
Chemical Substances	Glucocorticoids ; Biological Products
Language	English
Publishing date	2024-01-05
Publishing country	Switzerland
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1310211
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy.

Justicia, José L / Padró, Clara / Roger, Albert / Moreno, Francisco / Rial, Manuel J / Parra, Antonio / Valero, Antonio / Malet, Alfons / Teniente, Aina / Boronat, Anna / Torán-Barona, Carla

The World Allergy Organization journal

2021 Volume 14, Issue 6, Page(s) 100545

Abstract: Background: Despite the effectiveness of allergen immunotherapy (AIT), some patients are unresponsive for reasons still unknown; yet validated response biomarkers remain unavailable.: Objective: To analyze immunological parameters as biomarkers to ... ...

Abstract	Background: Despite the effectiveness of allergen immunotherapy (AIT), some patients are unresponsive for reasons still unknown; yet validated response biomarkers remain unavailable. Objective: To analyze immunological parameters as biomarkers to monitor and predict clinical response to a MicroCrystalline Tyrosine-adjuvanted house dust mite (HDM) AIT in patients with allergic rhinitis (AR). Methods: Observational, prospective, multicenter study including adult patients (aged 18-65 years) with AR, with and without asthma, sensitized to the HDM Results: Of 141 patients recruited, 118 (mean [SD] age of 33.6 [9.5] years) were evaluable. One year after treatment, Der p 1-specific IgE, DP-specific IgG4, and IL-10 increased by a mean (SD) of 3.4 (13.6) kU/L ( Conclusion: Non-responsive patients to AIT showed increased baseline IL-13 concentrations, suggesting its value as prognostic biomarker. DP-specific AIT increased Der p 1-specific IgE, DP-specific IgG4, and IL-10 concentrations in patients with AR. All patients benefited from treatment regardless of their sensitization profile to major DP allergens.
Language	English
Publishing date	2021-06-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2581968-9
ISSN	1939-4551
ISSN	1939-4551
DOI	10.1016/j.waojou.2021.100545
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee.

Turner, Paul J / Ansotegui, Ignacio J / Campbell, Dianne E / Cardona, Victoria / Carr, Stuart / Custovic, Adnan / Durham, Stephen / Ebisawa, Motohiro / Geller, Mario / Gonzalez-Estrada, Alexei / Greenberger, Paul A / Hossny, Elham / Irani, Carla / Leung, Agnes S Y / Levin, Michael E / Muraro, Antonella / Oppenheimer, John J / Ortega Martell, José Antonio / Pouessel, Guillaume /

Rial, Manuel J / Senna, Gianenrico / Tanno, Luciana K / Wallace, Dana V / Worm, Margitta / Morais-Almeida, Mário

The World Allergy Organization journal

2024 Volume 17, Issue 3, Page(s) 100876

Abstract: There is a lack of consensus over the description and severity assignment of allergic adverse reactions to immunotherapy, although there seems to be a consensus at least in terms of using the World Allergy Organization (WAO) grading systems to describe ... ...

Abstract	There is a lack of consensus over the description and severity assignment of allergic adverse reactions to immunotherapy, although there seems to be a consensus at least in terms of using the World Allergy Organization (WAO) grading systems to describe local adverse events for Sublingual Immunotherapy (SLIT) and Systemic Allergic Reactions (SARs) to Subcutaneous Immunotherapy (SCIT) amongst the major national/regional allergy societies. In this manuscript, we propose a modification of the previous WAO Grading system for SARs, which aligns with the newly-proposed Consortium for Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions in Food Allergy (version 3.0). We hope this can facilitate a unified grading system appropriate to SARs due to allergen immunotherapy, independent of allergen and route of administration, and across clinical and research practice.
Language	English
Publishing date	2024-02-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2581968-9
ISSN	1939-4551
ISSN	1939-4551
DOI	10.1016/j.waojou.2024.100876
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The validity of the Canadian clinical scores for occupational asthma in European populations.

Suarthana, Eva / Taghiakbari, Mahsa / Saha-Chaudhuri, Paramita / Rifflart, Catherine / Suojalehto, Hille / Hölttä, Pirjo / Walusiak-Skorupa, Jolanta / Wiszniewska, Marta / Muñoz, Xavier / Romero-Mesones, Christian / Sastre, Joaquín / Rial, Manuel J / Henneberger, Paul K / Vandenplas, Olivier

Allergy

2020 Volume 75, Issue 8, Page(s) 2124–2126

MeSH term(s)	Asthma, Occupational/diagnosis ; Asthma, Occupational/epidemiology ; Canada ; Humans ; Hypersensitivity ; Occupational Diseases ; Occupational Exposure/adverse effects
Language	English
Publishing date	2020-05-04
Publishing country	Denmark
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.14294
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾

Article: Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.

Cañas, José A / Valverde-Monge, Marcela / Rodrigo-Muñoz, José M / Sastre, Beatriz / Gil-Martínez, Marta / García-Latorre, Raquel / Rial, Manuel J / Gómez-Cardeñosa, Aida / Fernández-Nieto, Mar / Pinillos-Robles, Erwin J / Rodríguez-Nieto, María J / González-Mangado, Nicolás / Sastre, Joaquín / Pozo, Victoria Del

Journal of personalized medicine

2021 Volume 11, Issue 2

Abstract: Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit ...

Abstract	Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eight weeks of therapy, and a correlation was found between miR-1246 and eosinophil counts, including a number of exacerbations per year in these severe asthmatics. In silico pathway analysis revealed that these three miRNAs are regulators of the MAPK signaling pathway, regulating target genes implicated in asthma such as
Language	English
Publishing date	2021-01-28
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662248-8
ISSN	2075-4426
ISSN	2075-4426
DOI	10.3390/jpm11020076
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito